COVID-19 vaccine associated axillary lymphadenopathy – A systematic review
Authors:
Open Access
- 11 March 2022
- journal article
- review article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 31, 100546
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic PatientsRadiology, 2021
- Unilateral axillary Adenopathy in the setting of COVID-19 vaccineClinical Imaging, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workersInternational Journal of Infectious Diseases, 2021
- Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound FindingsBiology, 2021
- Lymphadenopathy Associated With the COVID-19 VaccineCureus, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020